Ayed-Guerfali et al. showed almost the same prevalence (3.75%), and using another evaluation criteria that considered abnormal the cases where betacatenin was not expressed or was expressed mainly in the nucleus and/or the cytoplasm, demonstrated the relationship between the abnormal pattern and patients in stages III and IV and with lymph node metastasis. The gene discussed is CTNNB1; the disease is metastatic malignant neoplasm in the lymph nodes.